TA-650 ( DrugBank: - )

4 diseases

ID	Disease name (Link within this page)	Number of trials
37	Generalised pustular psoriasis	1
56	Behcet disease	1
96	Crohn disease	2
97	Ulcerative colitis	2

37. Generalised pustular psoriasis

Clinical trials : 74 / Drugs : 53 - (DrugBank : 20) / Drug target genes : 20 - Drug target pathways : 101

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01680159 (ClinicalTrials.gov)	July 2012	28/8/2012	A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis		Plaque Psoriasis;Psoriatic Arthritis;Pustular Psoriasis (Excluding a Localized);Psoriatic Erythroderma	Drug: TA-650	Mitsubishi Tanabe Pharma Corporation	NULL	Completed	16 Years	75 Years	All	51	Phase 3	Japan

Clinical trials : 76 / Drugs : 110 - (DrugBank : 32) / Drug target genes : 36 - Drug target pathways : 116

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01532570 (ClinicalTrials.gov)	January 2012	6/2/2012	Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions	To Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Patients With Behcet's Disease ( BD ) With Special Lesions After the Administration of TA-650	Behcet's Disease;Behcet Syndrome;Neuro-Behcet's Disease	Drug: TA-650	Mitsubishi Tanabe Pharma Corporation	NULL	Completed	16 Years	75 Years	All	18	Phase 3	Japan

Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01580670 (ClinicalTrials.gov)	March 2012	3/4/2012	Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease	Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Pediatric Patients With Moderate to Severe Crohn's Disease	Pediatric Crohn's Disease	Drug: TA-650	Mitsubishi Tanabe Pharma Corporation	NULL	Completed	6 Years	17 Years	All	14	Phase 3	Japan
2	NCT00805766 (ClinicalTrials.gov)	December 2008	9/12/2008	Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)	Clinical Study to Assess the Efficacy and Safety of Increased Dose of TA-650 in Patients With Crohn's Disease (CD)	Crohn's Disease	Drug: TA-650	Mitsubishi Tanabe Pharma Corporation	NULL	Completed	16 Years	75 Years	All	39	Phase 3	Japan

Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01585155 (ClinicalTrials.gov)	February 2012	24/4/2012	Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis	Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Pediatric Patients With Moderate to Severe Ulcerative Colitis.	Pediatric Ulcerative Colitis	Drug: TA-650	Mitsubishi Tanabe Pharma Corporation	NULL	Completed	6 Years	17 Years	All	21	Phase 3	Japan
2	JPRN-JapicCTI-060298		24/08/2006	Clinical study to assess the efficacy and safety of TA-650 in patients with active ulcerative colitis	Clinical study to assess the efficacy and safety of TA-650 in patients with active ulcerative colitis	Ulcerative colitis	Intervention name : TA-650 (Infliximab) Dosage And administration of the intervention : Intravenous drip infusion	Mitsubishi Tanabe Pharma Corporation	NULL		16		BOTH		Phase 3	NULL